Date: 2016-01-11
Type of information: Grant
Company: Reneuron (UK)
Investors: Innovate UK (UK)
Amount: £2.1 million
Funding type: grant
Planned used: This grant will fund a collaborative programme of work to be undertaken by ReNeuron, as lead participant, and its collaborators on the grant, the Cell Therapy Catapult and the Department of Biochemical Engineering at University College London. This programme includes key pre-clinical development work packages relating to ReNeuron’s exosome nanomedicine platform. These include the development of robust manufacturing systems utilising scalable bioreactors and purification technologies that will enable the production of ReNeuron’s exosomes at a commercial scale. The work programme also includes product characterisation and potency assay development as well as pre-clinical efficacy and toxicity testing of the selected exosome nanomedicine candidate.
ReNeuron is exploiting the therapeutic potential of exosomes derived from its proprietary stem cell lines. The Company is also exploring the potential of its exosomes as a delivery system for gene therapy treatments. Exosomes are lipidbased nanoparticles secreted from all cells and which are believed to play a key role in the transfer of beneficial proteins and particularly non-coding RNAs from one cell to another. ReNeuron’s researchers have identified a novel mechanism by which exosomes from its clinical-grade CTX stem cells may inhibit the growth and migration of cancer cells in pre-clinical models of the disease.
Others: * On January 11, 2016, ReNeuron, a UK-based stem cell therapy development company, announced that it has been awarded a £2.1 million grant from Innovate UK to further advance its emerging exosome nanomedicine platform. The grant, entitled “Stem cell-derived exosomes for regenerative medicine”, has been awarded under Innovate UK’s Developing Regenerative Medicine & Cell
Therapies” grant scheme and will fund a collaborative programme of work to be undertaken by ReNeuron, as lead participant, and its collaborators on the grant, the Cell Therapy Catapult and the Department of Biochemical Engineering at University College London.
Therapeutic area: Regenerative Medicine
